Cholesterol News and Research

RSS

Cholesterol is a waxy, fat-like substance made in the liver, and found in the blood and in all cells of the body. Cholesterol is important for good health and is needed for making cell walls, tissues, hormones, vitamin D, and bile acid.

Prehypertension may increase risk of stroke

Even people with blood pressure that is slightly above normal may be at an increased risk of stroke, according to a review of studies published in the September 28, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

29 Sep 2011

Valeant's colesevelam New Drug Submission for hypercholesterolemia receives Canadian approval

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Valeant International (Barbados) SRL, has received notice that the New Drug Submission for colesevelam hydrochloride (colesevelam), an oral bile acid sequestrant for hypercholesterolemia, has been approved by the Canadian regulatory authority Health Canada.

28 Sep 2011

Takeda, AACE partner to launch Diabetes Navigator website

The American Association of Clinical Endocrinologists (AACE) and Takeda Pharmaceuticals North America Inc. (Takeda) have partnered to launch the Diabetes Navigator, a compendium capturing a selection of useful and reliable type 2 diabetes information available online for patients and caregivers.

28 Sep 2011

Lovastatin appears to be safe, effective for children with neurofibromatosis type 1

Researchers at Children's National Medical Center have found that a cholesterol-lowering statin drug appears to be safe in children with neurofibromatosis type 1 (NF1) and may improve learning disabilities, including verbal and nonverbal memory.

28 Sep 2011

A Daddy’s heart is healthier: Study

A new study shows that fathers are less likely to die of heart disease than men who’ve never had kids. This raises questions about a possible biological link between male infertility and overall health. Other recent studies have found a connection between testicular and prostate cancer and infertility.

27 Sep 2011

NYU Langone to lead NVVLS on long-term effects of PTSD

NYU Langone Medical Center announced that Charles R. Marmar, MD, the Lucius N. Littauer Professor of Psychiatry and chair of the Department of Psychiatry, was selected to lead the clinical evaluation component of a national survey — the National Vietnam Veterans Longitudinal Study (NVVLS) — on the long-term effects of combat-related post-traumatic stress disorder (PTSD) and other related health conditions on Vietnam veterans.

27 Sep 2011

Researchers modify HIV in a way that makes it no longer able to suppress immune system

Researchers at Johns Hopkins have modified HIV in a way that makes it no longer able to suppress the immune system. Their work, they say in a report published online September 19 in the journal Blood, could remove a major hurdle in HIV vaccine development and lead to new treatments.

27 Sep 2011

Potato consumption leads to higher overall diet quality

A frequently expressed concern in the ongoing public health debate is that fresh fruits and vegetables, particularly those that are nutrient dense, are not affordable to the average consumer. Research presented today at the American Dietetic Association's (ADA) Food and Nutrition Conference and Expo (FNCE) demonstrates that potatoes are one of the best nutritional values in the produce department, providing significantly better nutritional value per dollar than most other raw vegetables.

27 Sep 2011

Eating blueberries may inhibit breast cancer tumor growth

Eating blueberries may inhibit breast cancer tumor growth, according to a recent study by researchers at the City of Hope in Los Angeles that is published in the October 2011 issue of The Journal Of Nutrition and featured in the September issue of Food Nutrition & Science.

27 Sep 2011

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia.

27 Sep 2011

Roundup: Patient dies after medical error during Calif. nurses strike; grocery workers ratify contract that had partially hinged on health care

Veteran nurses locked out of Alta Bates Summit Medical Center in Oakland said Sunday that the death of a patient due to a medical error by a replacement worker wouldn't have happened if they had been allowed to do their jobs. The hospital's management countered that it was a freak accident that could have happened at any time -- with or without the replacement nurses. At the center of the dispute is a cancer patient, a woman who has not been identified but whose tragic death on Saturday has inflamed an already tense labor dispute.

27 Sep 2011

Scientists reveal link between lipid cell dysfunction and metabolic diseases

By measuring the radioactive isotope carbon-14, scientists at Karolinska Institutet have revealed an association between lipid cell dysfunction and diseases such as obesity, diabetes and blood lipid disorders.

26 Sep 2011

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.

26 Sep 2011

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

A pivotal Phase III study shows Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.

26 Sep 2011

Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer

Regeneron Pharmaceuticals, Inc. today announced that additional data from the Phase 3 VELOUR trial will be presented at the 2011 European Multidisciplinary Cancer Congress (EMCC) which will take place from September 23-27 in Stockholm, Sweden.

26 Sep 2011

Six ways to prevent coronary artery disease

In honor of National Cholesterol Education Month, Hotze Health & Wellness Center (HHWC) is encouraging both men and women to take a proactive role in healthy aging, specifically heart disease prevention. HHWC is advocating effective measures to prevent heart attacks and is shedding new light on cholesterol myths and the dangers of cholesterol-lowering (statin) drugs.

23 Sep 2011

New insights into nephrotic syndrome and high blood pressure

Scientists have now begun to understand kidney damage on a cellular level and how the activity of certain molecules in damaged kidneys contributes to salt and water retention in nephrotic syndrome.

23 Sep 2011

Soy protein reduces progression of atherosclerosis in women within 5 years of menopause

A new study published in the November 2011 issue of Stroke reveals some promising data on the positive effects of soy protein reducing the progression of clogged arteries in women who were within five years of menopause. This study was the largest and longest randomized controlled human study conducted to-date that directly investigated the efficacy of isolated soy protein consumption on the progression of atherosclerosis.

23 Sep 2011

AHA certifies walnuts as heart-healthy food

California Walnuts is proud to announce that the American Heart Association is now certifying walnuts as a heart-healthy food. The Heart-Check mark easily identifies foods that meet the nutritional standards set by the American Heart Association and provides consumers a quick and reliable way to identify heart-healthy foods.

23 Sep 2011

Ambrx, Bristol-Myers Squibb collaborate for novel biologics to treat heart failure and diabetes

Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.

23 Sep 2011

Cholesterol News and Research

Further Reading

Prehypertension may increase risk of stroke

Valeant's colesevelam New Drug Submission for hypercholesterolemia receives Canadian approval

Takeda, AACE partner to launch Diabetes Navigator website

Lovastatin appears to be safe, effective for children with neurofibromatosis type 1

A Daddy’s heart is healthier: Study

NYU Langone to lead NVVLS on long-term effects of PTSD

Researchers modify HIV in a way that makes it no longer able to suppress immune system

Potato consumption leads to higher overall diet quality

Eating blueberries may inhibit breast cancer tumor growth

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Roundup: Patient dies after medical error during Calif. nurses strike; grocery workers ratify contract that had partially hinged on health care

Scientists reveal link between lipid cell dysfunction and metabolic diseases

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer

Six ways to prevent coronary artery disease

New insights into nephrotic syndrome and high blood pressure

Soy protein reduces progression of atherosclerosis in women within 5 years of menopause

AHA certifies walnuts as heart-healthy food

Ambrx, Bristol-Myers Squibb collaborate for novel biologics to treat heart failure and diabetes

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News